



Respiratory: EOSINOPHIL - ADHESION ASSAY - ASTHMA

OBJECTIVES

To determine **novel** anti-inflammatory effects of **MLK** on resting and GM-CSF-stimulated **eosinophils** using the **Cellix VenaFlux™** platform to mimic physiological adhesion to rhVCAM-1

INTRODUCTION

Asthma is one of the most common chronic respiratory diseases in developed countries. For the majority of asthmatics their symptoms are satisfactorily controlled by the regular use of inhaled glucocorticoids (GC). However, these drugs are not without side effects and some asthmatic patients derive only partial and in some cases no relief of their symptoms even when using high doses of GC. Clearly we need more effective therapy for asthma.

Eosinophils are key pro-inflammatory cells in the asthmatic lung where their cytotoxic products cause damage to the airway epithelium, tissue inflammation and airflow obstruction. Eosinophil adhesion to and transmigration through the endothelial cells lining the post-capillary venules are key events in their accumulation in the asthmatic lung. Understanding these mechanisms may lead to the identification of compounds that can blunt eosinophil accumulation. Activation of the cysteinyl leukotriene cysLT₁ receptor (cysLT₁R) results in eosinophil migration and damage to the mucus layer in the lung. Montelukast (MLK) is part of a new class of anti-asthma drugs that are antagonists to cysLT₁R reducing eosinophil migration. Evidence is accumulating that MLK may have additional anti-inflammatory effects on eosinophil function which were further investigated in this study.

METHODS

Refer to Application Note R200 for eosinophil isolation and flow assay details. Concentrations of adhesion proteins, mediators and drugs used were rhVCAM-1; 10 µg mL⁻¹, BSA; 10 µg mL⁻¹, GM-CSF; 10 ng mL⁻¹, LTC₄/D₄; 100 nM, MLK; 0.1 nM – 100 nM, MK571; 100 nM, MK886; 100 nM, Anti-α4β1; 10 µg mL⁻¹, anti-cysLT₁R; 10 µg mL⁻¹, Isotype Control; 10 µg mL⁻¹.

RESULTS

MLK (10 nM and 100 nM) gave partial (~40%) but significant (P<0.05) inhibition of unstimulated eosinophil adhesion to rhVCAM-1 at 2 dyne cm⁻² (Figure 1 and Figure 2). GM-CSF-stimulated eosinophil adhesion under flow was characterised by greater cell flattening with significant (P<0.05) inhibition of adherent cell numbers by 100 nM MLK observed (Figure 2). This effect appeared specific for MLK as the analogue MK571 had no significant effect on eosinophil adhesion to VCAM-1 (Figure 3). LTC₄ released from unstimulated or GM-CSF-treated eosinophils did not contribute to their adhesion to VCAM-1 as the leukotriene biosynthesis inhibitor MK886 had no inhibitory effect (Figure 3) while exogenously added LTC₄ did not enhance eosinophil adhesion (Table 1). In contrast, LTD₄ enhanced eosinophil adhesion to VCAM-1; an effect blocked by MLK (Table 1). Comparable observations were also made at 1 dyne cm⁻² (data not shown).




Figure 1: Representative experiment illustrating unstimulated eosinophil adhesion at 2 dyne cm⁻² to rhVCAM-1 together with the inhibitory effects of pre-incubation with 100nM MLK.



Non- & GM-CSF-Stimulated Eosinophil Adhesion to VCAM-1 at 2 dyne cm⁻²
Montelukast Dose Response




Figure 2: Dose response of the effect of MLK on non-stimulated and GM-CSF-stimulated eosinophil adhesion to rhVCAM-1 under flow conditions of 2 dyne cm⁻² (n=4, *P<0.05).

Non- & GM-CSF-Stimulated Eosinophil Adhesion to VCAM-1 at 2 dyne cm⁻²
Effect of MK571, MK 886 and CysLT1 Ab




Figure 3: Effect of MLK, the montelukast an MK571 and the leukotriene biosynthesis inhibitor MK886, on unstimulated or GM-CSF-stimulated eosinophil adhesion to rhVCAM-1. Data expressed as a percentage of non-stimulated eosinophil adhesion at 2 dyne cm⁻² (n=4, *P<0.05).

Conditions	Change in adhesion at 2 dyne cm ⁻² (%)
Nil	100 ± 0.0
100nM LTC4	111.8 ± 40.6
100nM LTD4	187.1 ± 7.4*
100nM LTD4 + 10nM MLK	103.3 ± 31.7**
100nM LTD4 + 100nM MLK	43.8 ± 19.4**
100nM LTD4 + anti-CysLT ₁ R	111.6 ± 35.9**
100nM LTD4 + isotope control Ab	155.1 ± 10.4

* denotes significance (p<0.005), compared to Nil ** denotes significance (p<0.005), compared to LTD4

Table 1: The effect of MLK and an anti-CysLT₁R antibody on non-stimulated and LTC₄/D₄-stimulated eosinophil adhesion to rhVCAM-1 at dyne cm⁻². (n=4).

CONCLUSIONS

- Physiologically relevant concentrations of MLK inhibited resting and GM-CSF-stimulated eosinophil adhesion to VCAM-1 in an *in vitro* model of the post-capillary venules.
- Inhibitory effects by MLK appeared independent of cysLT₁R blockade.
- Our study confirms a previous report that MLK inhibited transmigration of eosinophils across human umbilical vein endothelial cells under static conditions².
- These findings may provide important clues for developing novel therapy aimed at blunting eosinophil-induced inflammation in allergic-based disease.

REFERENCES

- 1 Robinson A.J., Khashanin D, O'Dowd F, Williams V. and Walsh G.M. (2008) Montelukast inhibition of resting and GM-CSF -stimulated eosinophil adhesion to VCAM-1 under flow conditions appears independent of CysLT1 antagonism *Journal of Leukocyte Biology* (in press).
- 2 Virchow Jr., J.C., Faehndrich, S., Nassenstein, C., Bock, S., Matthys, H., & Luttmann, W. (2001). Effect of a specific cysteinyl leukotriene receptor antagonist (montelukast) on the transmigration of eosinophils across human umbilical vein endothelial cells. *Clin. Exp. Allergy*, 31, 836-844.

©2008 Cellix Limited. All rights reserved.